3 not yet recruiting, 1 unknown. 4 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Not yet recruiting 3, Unknown 1 |
Follow dalpiciclib: new trials by email Literature Review of dalpiciclib trials Research Report on dalpiciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer Dalpiciclib, Abemaciclib/Ribociclib - Breast Cancer | Not applicable | Not yet recruiting | Henan Cancer Hospital | 456 | 2026-11-01 | 2026-10-27 |
| The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment Ribociclib; abemaciclib; palbociclib; Dalpiciclib - Breast Cancer Stage III, Breast Cancer Stage II | Not applicable | Not yet recruiting | Hongmei Zheng, PhD | 40 | 2025-04-01 | 2025-03-17 |
| Albumin-bound PaclitaxelăDalpiciclib and AI in ER-Low (1%-10%) HER2-ABC Dalpiciclib - HR+/HER2- Advanced Breast Cancer | Not applicable | Not yet recruiting | Fujian Medical University | 52 | 2025-01-01 | 2024-12-02 |
| An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer Dalpiciclib and Letrozole Combined With Anlotinib - Breast Cancer | Not applicable | Unknown | Liu Shu | 30 | 2024-10-31 | 2024-09-20 |
Breast Neoplasms (3)
Fujian Medical University (1) · Henan Cancer Hospital (1) · Hongmei Zheng, PhD (1) · Liu Shu (1)